HomeComparePKI vs MET

PKI vs MET: Dividend Comparison 2026

PKI yields 0.24% · MET yields 3.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MET wins by $21.6K in total portfolio value
10 years
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →
MET
MET
● Live price
3.33%
Share price
$68.27
Annual div
$2.27
5Y div CAGR
23%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.3K
Annual income
$4,879.85
Full MET calculator →

Portfolio growth — PKI vs MET

📍 MET pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKIMET
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKI + MET cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKI pays
MET pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
MET
Annual income on $10K today (after 15% tax)
$282.63/yr
After 10yr DRIP, annual income (after tax)
$4,147.87/yr
At 15% tax rate, MET beats the other by $4,147.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKI + MET for your $10,000?

PKI: 50%MET: 50%
100% MET50/50100% PKI
Portfolio after 10yr
$30.5K
Annual income
$2,439.93/yr
Blended yield
8.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MET right now

PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
MET
Analyst Ratings
24
Buy
8
Hold
Consensus: Buy
Price Target
$96.83
+41.8% upside vs current
Range: $90.00 — $101.00
Altman Z
0.1
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKI buys
0
MET buys
8
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$MET▼ Sell$1,001 - $15,0002025-08-26
Ro Khanna🏢 House$MET▼ Sell$1,000 - $15,0002025-08-26
Gilbert Cisneros🏢 House$MET▼ Sell$1,001 - $15,0002025-08-06
Ritchie Torres🏢 House$MET▼ Sell$1,001 - $15,0002025-07-11
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002025-06-13
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002024-11-19
Thomas R. Carper🏛 Senate$MET▼ Sell$1,001 - $15,0002024-01-17
Ro Khanna🏢 House$MET▲ Buy$1,001 - $15,0002023-10-31
Sheldon Whitehouse🏛 Senate$MET▼ Sell$1,001 - $15,0002023-09-20
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKIMET
Forward yield0.24%3.33%
Annual dividend / share$0.28$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%23%
Portfolio after 10y$19.7K$41.3K
Annual income after 10y$0.02$4,879.85
Total dividends collected$24.00$18.1K
Payment frequencyquarterlyquarterly
SectorStockFinancials
Analyst consensusHoldBuy
Analyst price target$166.57$96.83

Year-by-year: PKI vs MET ($10,000, DRIP)

YearPKI PortfolioPKI Income/yrMET PortfolioMET Income/yrGap
1← crossover$10,712$12.15$11,109$408.98$397.00MET
2$11,468$6.08$12,409$522.27$941.00MET
3$12,274$3.04$13,948$670.62$1.7KMET
4$13,135$1.52$15,791$866.52$2.7KMET
5$14,055$0.76$18,024$1,127.71$4.0KMET
6$15,039$0.38$20,765$1,479.66$5.7KMET
7$16,092$0.19$24,179$1,959.61$8.1KMET
8$17,218$0.10$28,494$2,622.90$11.3KMET
9$18,424$0.05$34,042$3,553.25$15.6KMET
10$19,713$0.02$41,305$4,879.85$21.6KMET

PKI vs MET: Complete Analysis 2026

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →

METFinancials

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.

Full MET Calculator →
📬

Get this PKI vs MET comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKI vs SCHDPKI vs JEPIPKI vs OPKI vs KOPKI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.